A decade of research on the 17q12-21 asthma locus: Piecing together the puzzle - 06/09/18
Abstract |
Chromosome 17q12-21 remains the most highly replicated and significant asthma locus. Genotypes in the core region defined by the first genome-wide association study correlate with expression of 2 genes, ORM1-like 3 (ORMDL3) and gasdermin B (GSDMB), making these prime candidate asthma genes, although recent studies have implicated gasdermin A (GSDMA) distal to and post-GPI attachment to proteins 3 (PGAP3) proximal to the core region as independent loci. We review 10 years of studies on the 17q12-21 locus and suggest that genotype-specific risks for asthma at the proximal and distal loci are not specific to early-onset asthma and mediated by PGAP3, ORMDL3, and/or GSDMA expression. We propose that the weak and inconsistent associations of 17q single nucleotide polymorphisms with asthma in African Americans is due to the high frequency of some 17q alleles, the breakdown of linkage disequilibrium on African-derived chromosomes, and possibly different early-life asthma endotypes in these children. Finally, the inconsistent association between asthma and gene expression levels in blood or lung cells from older children and adults suggests that genotype effects may mediate asthma risk or protection during critical developmental windows and/or in response to relevant exposures in early life. Thus studies of young children and ethnically diverse populations are required to fully understand the relationship between genotype and asthma phenotype and the gene regulatory architecture at this locus.
Le texte complet de cet article est disponible en PDF.Key words : Wheezing, genome-wide association study, immune cells, lung cells, ORMDL3, GSDMB, PGAP3, GSDMA, gene expression
Abbreviations used : ASMC, BEC, CEU, COPSAC, CTCF, eQTL, ERBB2, ETS, GPI, GSDMA, GSDMB, GWAS, IKZF3, LCL, LD, OR, ORMDL3, PBL, PCA, PGAP3, SNP, TRM, YRI, ZPBP2
Plan
Supported by grants R01 HL085197, P01 HL070831, R01 HL129735, U19 AI095230, R01 HL122712, and R01 HL113395. K.M.M. and C.W. are supported by grant T32 GM007197, and M.M.S., N.S., and B.A.H. are supported by grant T32 HL007605. |
|
Disclosure of potential conflict of interest: K. Bønnelykke has received grants from the Lundbeck Foundation, Novo Nordisk Foundation, the Danish Ministry of Health, the Danish Strategic Research Foundation, and the National Institutes of Health (grant no. NHLBI R01 HL129735). The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 3
P. 749 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?